Treatment of primary intraocular melanoma

Expert Review of Anticancer Therapy

Volumn 6, Issue 4, 2006, Pages 493-506

  Damato, Bertil ^a  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Eye; Melanoma; Patient; Treatment; Uvea; Uveal neoplasms

Indexed keywords

INDOCYANINE GREEN; IODINE 125; RUTHENIUM 106; STEROID; ANTINEOPLASTIC AGENT;

ARTICLE; ASPIRATION BIOPSY; BRACHYTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHOROID MELANOMA; CHROMOSOME 3; CHROMOSOME ABERRATION; CHROMOSOME LOSS; CILIARY BODY TUMOR; DIODE LASER; DISEASE CONTROL; ECHOGRAPHY; ENUCLEATION; EYE CANCER; EYE SURGERY; FLUORESCENCE ANGIOGRAPHY; GLAUCOMA; HUMAN; HYPERTHERMIC THERAPY; INDOCYANINE GREEN ANGIOGRAPHY; IRIS TUMOR; LIVER METASTASIS; LOW LEVEL LASER THERAPY; MEDICAL PHOTOGRAPHY; MELANOMA; NEOVASCULAR GLAUCOMA; PHOTON THERAPY; PROTON THERAPY; PSYCHOLOGICAL ASPECT; TREATMENT INDICATION; UVEA MELANOMA; VISUAL ACUITY; VISUAL IMPAIRMENT; VISUAL SYSTEM EXAMINATION; VITREOUS HEMORRHAGE; EYE TUMOR; MORTALITY; REVIEW; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; EYE NEOPLASMS; HUMANS; MELANOMA; SURVIVAL RATE;

EID: 33746290776     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.4.493     Document Type: Article

References (87)

1. Damato B. Detection of uveal melanoma by optometrists in the United Kingdom. Ophthalmic Physiol. Opt. 21, 268-271 (2001).
2. Ah-Fat FG, Damato BE. Delays in the diagnosis of uveal melanoma and effect on treatment. Eye 12, 781-782 (1998).
3. Bove R, Char DH. Nondiagnosed uveal melanomas. Ophthalmology 111, 554-557 (2004).
4. Eskelin S, Kivelä T. Mode of presentation and time to treatment of uveal melanoma in Finland. Br. J. Ophthalmol. 86, 333-338 (2002).
5. Khan J, Damato BE. Accuracy of choroidal melanoma diagnosis by general ophthalmologists: a prospective study. Eye (2006) (E-pub ahead of print).
6. Singh AD, Bergman L, Seregard S. Uveal melanoma: epidemiologic aspects. Ophthalmol. Clin. North Am. 18, 75-84 (2005).
7. Bataille V, Sasieni P, Cuzick J, Hungerford JL, Swerdlow A, Bishop JA. Risk of ocular melanoma in relation to cutaneous and iris naevi. Int. J. Cancer 60, 622-626 (1995).
8. Shields JA, Demirci H, Mashayekhi A, Shields CL. Melanocytoma of optic disc in 115 cases: the 2004 Samuel Johnson Memorial Lecture, part 1. Ophthalmology 111, 1739-1746 (2004).
9. Melia BM, Diener-West M, Bennett SR, Folk JC. Factors predictive of growth and treatment of small choroidal melanoma. Arch. Ophthalmol. 115, 1537-1544 (1997).
10. Singh AD, Rennie IG, Seregard S, Giblin M, McKenzie J. Sunlight exposure and pathogenesis of uveal melanoma. Surv. Ophthalmol. 49, 419-428 (2004).
11. Kujala E, Mäkitie T, Kivelä T. Very long-term prognosis of patients with malignant uveal melanoma. Invest. Ophthalmol. Vis. Sci. 44, 4651-4659 (2003).
12. Kujala E, Kivelä T. Tumor, node, metastasis classification of malignant ciliary body and choroidal melanoma evaluation of the 6th edition and future directions. Ophthalmology 112, 1135-1144 (2005).
13. McLean IW, Saraiva VS, Burnier MN Jr. Pathological and prognostic features of uveal melanomas. Can. J. Ophthalmol. 39, 343-350 (2004).
14. Folberg R, Hendrix MJ, Maniotis AJ. Vasculogenic mimicry and tumor angiogenesis. Am. J. Pathol. 156, 361-381 (2000).
15. Al-Jamal RT, Mäkitie T, Kivelä T. Nucleolar diameter and microvascular factors as independent predictors of mortality from malignant melanoma of the choroid and ciliary body. Invest. Ophthalmol. Vis. Sci. 44, 2381-2389 (2003).
16. + cells) and prognosis in malignant uveal melanoma. Invest. Ophthalmol. Vis. Sci. 42, 1414-1421 (2001).
17. Ericsson C, Seregard S, Bartolazzi A et al. Association of HLA class I and class II antigen expression and mortality in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 42, 2153-2156 (2001).
18. Singh AD, Damato B, Howard P, Harbour JW. Uveal melanoma: genetic aspects. Ophthalmol. Clin. North Am. 18, 85-97, viii (2005).
19. Tschentscher F. Husing J, Holter T et al. Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res. 63, 2578-2584 (2003).
20. Egan KM, Ryan LM, Gragoudas ES. Survival implications of enucleation after definitive radiotherapy for choroidal melanoma: an example of regression on time-dependent covariates. Arch. Ophthalmol. 116, 366-370 (1998).
21. Augsburger JJ, Gamel JW, Shields JA, Markoe AM, Brady LW. Post-irradiation regression of choroidal melanomas as a risk factor for death from metastasic disease. Ophthalmology 94, 1173-1177 (1987).
22. Mudhar HS, Parsons MA, Sisley K, Rundle P, Singh A, Rennie IG. A critical appraisal of the prognostic and predictive factors for uveal malignant melanoma. Histopathology 45, 1-12 (2004).
23. Eskelin S, Pyrhonen S, Hahka-Kemppinen M, Tuomaala S, Kivelä T. A prognostic model and staging for metastatic uveal melanoma. Cancer 97, 465-475 (2003).
24. Muscat S, Parks S, Kemp E. Keating D. Secondary retinal changes associated with choroidal naevi and melanomas documented by optical coherence tomography. Br. J. Ophthalmol. 88, 120-124 (2004).
25. The Collaborative Ocular Melanoma Study Group. Factors predictive of growth and treatment of small choroidal melanoma. COMS report no. 5. Arch. Ophthalmol. 115, 1537-1544 (1997).
26. Augsburger JJ, Correa ZM, Schneider S et al. Diagnostic transvitreal fine-needle aspiration biopsy of small melanocytic choroidal tumors in nevus versus melanoma category. Trans. Am. Ophthalmol. Soc. 100, 225-232 (2002).
27. Diener-West M, Reynolds SM, Agugliaro DJ et al. Screening for metastasis from choroidal melanoma: the Collaborative Ocular Melanoma Study Group Report 23. J. Clin. Oncol. 22, 2438-2444 (2004).
28. Eskelin S, Pyrhonen S, Summanen P, Prause JU, Kivelä T. Screening for metastatic malignant melanoma of the uvea revisited. Cancer 85, 1151-1159 (1999).
29. Finger PT, Kurli M, Wesley P, Tena L, Kerr KR, Pavlick A. Whole body PET/ CT imaging for detection of metastatic choroidal melanoma. Br. J. Ophthalmol. 88, 1095-1097 (2004).
30. Finger PT. Intraoperative echographic localization of iodine-125 episcleral plaque for brachytherapy of choroidal melanoma. Am. J. Ophthalmol. 130, 539-540 (2000).
31. Astrahan MA, Luxton G, Pu Q, Petrovich Z. Conformal episcleral plaque therapy. Int. J. Radiat. Oncol. Biol. Phys. 39, 505-519 (1997).
32. Missotten L, Dirven W, Van dS, Leys A, De MG, Van LE. Results of treatment of choroidal malignant melanoma with high dose-rate strontium-90 brachytherapy. A retrospective study of 46 patients treated between 1983 and 1995. Graefes Arch. Clin. Exp. Ophthalmol. 236. 164-173 (1998).
33. Finger PT, Berson A, Ng T, Szechter A. Palladium-103 plaque radiotherapy for choroidal melanoma: an 11-year study. Int. J. Radiat. Oncol. Biol. Phys. 54, 1438-1445 (2002).
34. 106Ru brachytherapy of choroidal melanoma. Int. J. Radiat. Oncol. Biol. Phys. 63, 385-391 (2005).
35. Astrahan MA. Improved treatment planning for COMS eye plaques. Int. J. Radiat. Oncol. Biol. Phys. 61, 1227-1242 (2005).
36. 106 brachytherapy of choroidal melanomas. Int. J. Radiat. Oncol. Biol. Phys. 63, 392-400 (2005).
37. Shields CL, Cater J, Shields JA et al. Combined plaque radiotherapy and transpupillary thermotherapy for choroidal melanoma: tumor control and treatment complications in 270 consecutive patients. Arch. Ophthalmol. 120, 933-940 (2002).
38. Jampol LM, Moy CS, Murray TG et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19. Ophthalmology 109, 2197-2206 (2002).
39. Jensen AW, Petersen IA, Kline RW, Stafford SL, Schomberg PJ, Robertson DM. Radiation complications and tumor control after 125I plaque brachytherapy for ocular melanoma. Int. J. Radiat. Oncol. Biol. Phys. 63, 101-108 (2005).
40. Sobrin L, Schiffman JC, Markoe AM, Murray TG. Outcomes of iodine 125 plaque radiotherapy after initial observation of suspected small choroidal melanomas: a pilot study. Ophthalmology 112, 1777-1783 (2005).
41. Melia BM, Abramson DH, Albert DM et al. Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report no. 16. Ophthalmology 108, 348-366 (2001).
42. Shields CL, Demirci H, Dai V et al. Intravitreal triamcinolone acetonide for radiation maculopathy after plaque radiotherapy for choroidal melanoma. Retina 25, 868-874 (2005).
43. Augsburger JJ, Schneider S, Freire J, Brady LW. Survival following enucleation versus plaque radiotherapy in statistically matched subgroups of patients with choroidal melanomas: results in patients treated between 1980 and 1987. Graefes Arch. Clin. Exp. Ophthalmol. 237, 558-567 (1999).
44. Diener-West M, Earle JD, Fine SL et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS report no. 18. Arch. Ophthalmol. 119, 969-982 (2001).
45. Vrabec TR, Augsburger JJ, Gamel JW, Brady LW, Hernandez C, Woodleigh R. Impact of local tumor relapse on patient survival after cobalt 60 plaque radiotherapy. Ophthalmology 98, 984-988 (1991).
46. Finger PT. Plaque radiation therapy for malignant melanoma of the iris and ciliary body. Am. J. Ophthalmol. 132, 328-335 (2001).
47. Shields CL, Naseripour M, Shields JA, Freire J, Cater J. Custom-designed plaque radiotherapy for nonresectable iris melanoma in 38 patients: tumor control and ocular complications. Am. J. Ophthalmol. 135, 648-656 (2003).
48. Gunduz K, Shields CL, Shields JA, Cater J, Brady L. Plaque radiotherapy for management of ciliary body and choroidal melanoma with extraocular extension. Am. J.Ophthalmol. 130, 97-102 (2000).
49. Gragoudas ES, Marie LA. Uveal melanoma: proton beam irradiation. Ophthalmol. Clin. North Am. 18, 111-118 (2005).
50. Damato B, Kacperek A, Chopra M, Campbell IR, Errington RD. Proton beam radiotherapy of choroidal melanoma: the Liverpool-Clatterbridge experience. Int. J. Radiat. Oncol. Biol. Phys. 62, 1405-1411 (2005).
51. Gragoudas ES, Lane AM, Munzenrider J, Egan KM, Li W. Long-term risk of local failure after proton therapy for choroidal/ciliary body melanoma. Trans. Am. Ophthalmol. Soc. 100, 43-48 (2002).
52. Gragoudas E, Li W, Goitein M, Lane AM, Munzenrider JE, Egan KM. Evidence-based estimates of outcome in patients irradiated for intraocular melanoma. Arch. Ophthalmol. 120, 1665-1671 (2002).
53. Gragoudas ES, Li W, Lane AM, Munzenrider J, Egan KM. Risk factors for radiation maculopathy and papillopathy after intraocular irradiation. Ophthalmology 106, 1571-1577 (1999).
54. Seddon JM, Gragoudas ES, Albert DM, Hsieh CC, Polivogianis L, Friedenberg GR. Comparison of survival rates for patients with uveal melanoma after treatment with proton beam irradiation or enucleation. Am. J. Ophthalmol. 99, 282-290 (1985).
55. Damato B, Kacperek A, Chopra M, Sheen MA, Campbell IR, Errington RD. Proton beam radiotherapy of iris melanoma. Int. J. Radiat. Oncol. Biol. Phys. 63, 109-115 (2005).
56. Mueller AJ, Schaller U, Talies S, Horstmann GA, Wowra B, Kampik A. Stereotactic radiosurgery using the Gamma Knife for large uveal melanomas. Ophthalmologe 100, 122-128 (2003).
57. Dieckmann K, Georg D, Zehetmayer M, Bogner J, Georgopoulos M, Potter R. LINAC based stereotactic radiotherapy of uveal melanoma: 4 years clinical experience. Radiother. Oncol. 67, 199-206 (2003).
58. Muller K, Nowak PJ, de Pan C et al. Effectiveness of fractionated stereotactic radiotherapy for uveal melanoma. Int. J. Radiat. Oncol. Biol. Phys. 63, 116-122 (2005).
59. Journee-de Korver HG, Midena E, Singh AD. Infrared thermotherapy: from laboratory to clinic. Ophthalmol. Clin. North Am. 18, 99 (2005).
60. Singh AD, Rundle PA, Berry-Brincat A, Parsons MA, Rennie IG. Extrascleral extension of choroidal malignant melanoma following transpupillary thermotherapy. Eye 18, 91-93 (2004).
61. Shields CL, Shields JA, Perez N, Singh AD, Cater J. Primary transpupillary thermotherapy for small choroidal melanoma in 256 consecutive cases: outcomes and limitations. Ophthalmology 109, 225-234 (2002).
62. De Potter P, Jamart J. Adjuvant indocyanine green in transpupillary thermotherapy for choroidal melanoma. Ophthalmology 110, 406-413 (2003).
63. Bartlema YM, Oosterhuis JA, Journee-de Korver JG, Tjho-Heslinga RE, Keunen JE. Combined plaque radiotherapy and transpupillary thermotherapy in choroidal melanoma: 5 years' experience. Br. J. Ophthalmol. 87, 1370-1373 (2003).
64. Char DH, Bove R, Phillips TL. Laser and proton radiation to reduce uveal melanoma-associated exudative retinal detachments. Am. J. Ophthalmol. 136, 180-182 (2003).
65. Damato BE, Foulds WS. Retina. Fourth Edition. Schachat AP, Ryan SJ, (Eds). Mosby, Inc., St Louis, MO, USA. 769-778 (2006).
66. Damato BE, Paul J, Foulds WS. Risk factors for residual and recurrent uveal melanoma after trans-scleral local resection. Br. J. Ophthalmol. 80, 102-108 (1996).
67. Damato BE. Adjunctive plaque radiotherapy after local resection of uveal melanoma. Front. Radiat. Ther. Oncol. 30, 123-132 (1997).
68. Damato BE, Paul J, Foulds WS. Predictive factors of visual outcome after local resection of choroidal melanoma. Br. J. Ophthalmol. 77, 616-623 (1993).
69. Damato BE, Paul J, Foulds WS. Predictive factors for metastasis after trans-scleral local resection of uveal melanoma. Br. J. Ophthalmol. 80, 109-116 (1996).
70. Kivelä T, Puusaari I, Damato B. Transscleral resection versus iodine brachytherapy for choroidal malignant melanomas 6 millimeters or more in thickness: a matched case-control study. Ophthalmology 110, 2235-2244 (2003).
71. Bechrakis NE, Bornfeld N, Zoller I, Foerster MH. Iodine 125 plaque brachytherapy versus transscleral tumor resection in the treatment of large uveal melanomas. Ophthalmology 109, 1855-1861 (2002).
72. Damato B, Groenewald C, McGalliard J, Wong D. Endoresection of choroidal melanoma. Br. J. Ophthalmol. 82, 213-218 (1998).
73. Hadden PW, Hiscott PS, Damato BE. Histopathology of eyes enucleated after endoresection of choroidal melanoma. Ophthalmology 111, 154-160 (2004).
74. Damato B, Wong D, Green FD, Mackenzie JM. Intrascleral recurrence of uveal melanoma after transretinal "endoresection". Br. J. Ophthalmol. 85, 114-145 (2001).
75. Bornfeld N, Talies S, Anastassiou G, Schilling H, Schuler A, Horstmann GA. Endoscopic resection of malignant melanomas of the uvea after preoperative stereotactic single dose convergence irradiation with the Leksell gamma knife. Ophthalmologe 99, 338-344 (2002).
76. Zimmerman LE, McLean IW, Foster WD. Does enucleation of the eye containing a malignant melanoma prevent or accelerate the dissemination of tumour cells. Br. J. Ophthalmol. 62, 420-425 (1978).
77. Hawkins BS. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24. Am. J. Ophthalmol. 138, 936-951 (2004).
78. Kilic E, Stijnen T, de Jong PT et al. Reduced melanoma-related mortality in uveal melanoma by preenucleation radiotherapy. Arch. Ophthalmol. 123, 1363-1367 (2005).
79. Damato B, Lecuona K. Conservation of eyes with choroidal melanoma by a multimodality approach to treatment: an audit of 1632 patients. Ophthalmology 111, 977-983 (2004).
80. Ah-Fat FG, Sharma MC, Damato BE. Taping outpatient consultations: a survey of attitudes and responses of adult patients with ocular malignancy. Eye 12, 789-791 (1998).
81. De Croock L, Verbraeken H. Metastatic uveal melanoma: diagnosis and treatment. A literature review. Bull. Soc. Belge Ophtalmol. 59-63 (2002).
82. Singh AD, Borden EC. Metastatic uveal melanoma. Ophthalmol. Clin. North Am. 18, 143-150, ix (2005).
83. Aoyama T, Mastrangelo MJ, Berd D et al. Protracted survival after resection of metastatic uveal melanoma. Cancer 89, 1561-1568 (2000).
84. Brandberg Y, Kock E, Oskar K, of Trampe E, Seregard S. Psychological reactions and quality of life in patients with posterior uveal melanoma treated with ruthenium plaque therapy or enucleation: a one year follow-up study. Eye 14, 839-846 (2000).
85. Reimer J, Esser J, Fleiss A et al. Quality of life in patients with malignant choroidal melanoma after radiotherapy. Graefes Arch. Clin. Exp. Ophthalmol. 241, 371-377 (2003).
86. Melia M, Moy CS, Reynolds SM et al. Quality of life after iodine 125 brachytherapy vs enucleation for choroidal melanoma: 5-year results from the Collaborative Ocular Melanoma Study: COMS QOLS Report No. 3. Arch. Ophthalmol. 124, 226-238 (2006).
87. Daftari IK, Char DH, Verhey LJ et al. Anterior segment sparing to reduce charged particle radiotherapy complications in uveal melanoma. Int. J. Radiat. Oncol. Biol. Phys. 39, 997-1010 (1997).